Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Purchased by DGS Capital Management LLC

DGS Capital Management LLC grew its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 528.2% during the 4th quarter, HoldingsChannel reports. The firm owned 74,993 shares of the company’s stock after buying an additional 63,056 shares during the period. DGS Capital Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $1,184,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of RDY. Lifestyle Asset Management Inc. boosted its position in Dr. Reddy’s Laboratories by 422.2% during the fourth quarter. Lifestyle Asset Management Inc. now owns 71,488 shares of the company’s stock worth $1,129,000 after acquiring an additional 57,799 shares during the last quarter. SG Americas Securities LLC purchased a new position in Dr. Reddy’s Laboratories in the 4th quarter worth approximately $145,000. Simon Quick Advisors LLC acquired a new position in shares of Dr. Reddy’s Laboratories during the 4th quarter worth approximately $224,000. Atomi Financial Group Inc. purchased a new stake in shares of Dr. Reddy’s Laboratories in the fourth quarter valued at approximately $162,000. Finally, Crossmark Global Holdings Inc. increased its holdings in shares of Dr. Reddy’s Laboratories by 328.3% in the fourth quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company’s stock valued at $201,000 after purchasing an additional 9,781 shares during the last quarter. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

NYSE:RDY opened at $14.02 on Friday. The company has a market capitalization of $11.70 billion, a P/E ratio of 22.39 and a beta of 0.51. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 52 week low of $13.61 and a 52 week high of $16.89. The stock’s fifty day moving average is $14.86 and its two-hundred day moving average is $15.52.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.81% and a return on equity of 18.53%. Equities analysts expect that Dr. Reddy’s Laboratories Limited will post 0.81 EPS for the current year.

Analyst Upgrades and Downgrades

RDY has been the topic of a number of recent research reports. Barclays lowered their price objective on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Finally, Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.